Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.87 |
| ▸ | MEN1 | O00255 | 5/20 | 0.87 |
| ▸ | MAPT | P10636 | 4/20 | 0.87 |
| ▸ | GAA | P10253 | 3/20 | 0.87 |
| ▸ | USP2 | O75604 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | HTT | P42858 | 2/20 | 0.87 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | APAF1 | O14727 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158776 | 0.93 | KMT2A (1.00) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL5448612 | 0.89 | KMT2A (0.80) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL10159118 | 0.87 | MAPT (0.81) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL17717925 | 0.87 | MEN1 (1.00) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL3421314 | 0.85 | KMT2A (0.74) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL10159035 | 0.83 | MAPT (0.81) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL11789844 | 0.83 | KMT2A (0.81) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL19998149 | 0.83 | KMT2A (0.71) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL10158775 | 0.83 | MAPT (0.80) | KMT2AMEN1MAPTGAAUSP2 | |
| SCHEMBL3419510 | 0.83 | KMT2A (0.80) | KMT2AMEN1MAPTGAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-22 | — | — | US | claimed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3144299-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Cambria Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010129665-A2 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-7700774-B2 | Heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-04-20 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | KMT2A 946/4885MEN1 4617/4885MAPT 6/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | KMT2A 652/4885MEN1 3602/4885MAPT 4577/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | KMT2A 673/4885MEN1 3831/4885MAPT 4599/4885 |
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | LIPC, PCSK9, PC | KMT2A 3247/4885MEN1 1019/4885MAPT 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.